Author

Y.-T. Yang

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. Al-Janadi· 1 shared A. Vanecek· 1 shared C. Taylor· 1 shared C.-C. Chen· 1 shared C.-C. Hsu· 1 shared C.-T. Ho· 1 shared D. Isaac· 1 shared E. Elsworth· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. Al-Janadi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Dietary Exposure to Antibiotic Residues Facilitates Metabolic Disorder by Altering the Gut Microbiota and Bile Acid Composition

R.-A. Chen, W.-K. Wu, S. Panyod, P.-Y. Liu, H.-L. Chuang, Y.-H. Chen, Q. Lyu, H.-C. Hsu, T.-L. Lin, T.-C. D. Shen, Y.-T. Yang, H.-B. Zou, H.-S. Huang, Y.-E. Lin, C.-C. Chen, , L.-Y. Sheen

This study shows that low-dose antibiotic residue exposure in early life alters gut microbiota and bile acid composition, leading to long-term metabolic disorders in mice.

bioRxiv · Jul 6, 2021Microbiology

Enhancing c-MYC degradation via 20S proteasome activation induces in vivo anti-tumor efficacy

E. Njomen, T. Lansdell, A. Vanecek, V. Benham, M. Bernard, Y.-T. Yang, P. Schall, D. Isaac, O. Alkharabsheh, A. Al-Janadi, m. Giletto, E. Elsworth, C. Taylor, T. Yang, m. Bailie, , J. Tepe

This study shows that activating the 20S proteasome with small molecules reduces c-MYC-driven cancer growth in vitro and in vivo, including in bortezomib-resistant cells.

bioRxiv · Aug 24, 2020 · PreprintPharmacology & Toxicology